Navigation Links
Hepatitis in Biological News

The hepatitis healing power of blueberry leaves

A chemical found in blueberry leaves has shown a strong effect in blocking the replication of the Hepatitis C virus, opening up a new avenue for treating chronic HCV infections, which affect 200 million people worldwide and can eventually lead to cirrhosis and liver cancer. Among the areas of ...

First human gets new antibody aimed at hepatitis C virus

Boston, Mass. Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed ...

Novel antibody prevents infection by hepatitis C virus

Boston, Mass. Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV...

Biolex presents Locteron US Phase 2a hepatitis C data at EASL

Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron will be presented today at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. Locteron, controlled-release i...

When acute hepatitis develops into chronic hepatitis

To achieve this, Carlos A. Guzmn, Head of the "Vaccinology and Applied Microbiology" working group and Robert Geffers, Head of the "Gene Expression Analysis" platform, examined the incidence and species of special defence cells, T helper cells, along with their role in the development of the disea...

Discovery could lead to a new animal model for hepatitis C

During its career, the potentially fatal hepatitis C virus has banked its success on a rather unusual strategy: its limitations. Its inability to infect animals other than humans and chimpanzees has severely hampered scientists in developing a useful small animal model for the disease. But now, in...

Leeds research points to new therapy for hepatitis C treatment

Combination therapies similar to those used for HIV patients may be the best way of treating hepatitis C virus (HCV), say researchers from the University of Leeds. A study of a protein called p7, has revealed that differences in the genetic coding of the protein between virus strains - known a...

Nano vaccine for hepatitis B shows promise for third world

ANN ARBOR, Mich. Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an e...

BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients

(PRINCETON, NJ, March 24, 2008) New BARACLUDE (entecavir) data presented today demonstrated a continued low incidence of resistance in nucleoside-nave patients through five years of treatment. In the nucleoside-nave chronic hepatitis B patients analyzed, no additional patient developed resistanc...

New hope for hepatitis C sufferers

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers. University of Adelaide virologists Dr Michael Beard and Dr Karla Helbig will work with colleagues from the University of NSW to develop new strateg...

Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic

HORSHAM, PA (January 11, 2008): Nucleonics, Inc., a privately held biotechnology company focused on the development of novel RNA interference (RNAi)-based therapeutics, announced today that the company has begun treating patients in a Phase 1 human safety study of its experimental treatment for c...

Eltrombopag effective for hepatitis C patients with low blood-platelet counts

NEW YORK (Dec. 28, 2007) -- For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease. This problem is compounded by the fact that standard antiviral treatment for the disease can further reduce platelet numbers to dangerously low ...

Possible hepatitis C vaccine

Hepatitis C Virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed. It is the single biggest cause of people requiring a liver transplant in Britain. Now, in a collaborative effort with groups across Europe and the USA, scientists from The University of ...

Who will recover spontaneously from hepatitis C virus infection

More than 3% of world population is infected with hepatitis C virus (HCV). The outcome of HCV infections is either self recovery or chronic hepatitis, and many of the chronic infections will develop into liver cirrhosis or liver cancer. Since there is no cure for chronic hepatitis C, nor is there ...

Clearance of hepatitis C viral infection after liver transplantation

Touching stories of living donor transplantation are continuously happening in hospitals. One of these stories is reported recently in the August 14 issue of the World Journal of Gastroenterology because of its shining significance in hepatology. This article is going to bring comfort to many fami...

Liver cancer patients with high serum levels of hepatitis B virus face poorer outcomes

In the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD), researchers report their findings from the first-ever study examining the prognostic value of serum HBV DNA levels for patients with liver ca...

Risk of lymphoma increases with hepatitis C virus infection

People infected with the hepatitis C virus (HCV) are at an increased risk of developing certain lymphomas (cancers of the lymphatic system), according to a study published in the May 8, 2007, issue of the Journal of the American Medical Association. Researchers from the National Cancer Institute (...

Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses

Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common. The two are far apart genetically, are transmitted differently, and produce very different diseases. Hepatitis A spreads through the consumption of fecal particles from an ...

New culture method for hepatitis C virus uses primary hepatocytes and patient serum

Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines. The related report by Lázaro et al, "Hepati...

Protein found that slows hepatitis C growth in liver cells

Biomedical researchers have identified a cellular protein that interferes with hepatitis C virus replication, a finding that ultimately may help scientists develop new drugs to fight the virus. The anti-hepatitis C activity of the protein, called “p21-activated kinase 1?(PAK1), was discovered by ...

New test helps identify hepatitis C patients at high risk of developing cirrhosis

A researcher at the Stanford University School of Medicine has helped confirm the reliability of a new test for liver disease that is ushering in the long-promised era of personalized medicine based on each individual's genetic makeup. The Stanford group was one of the five sites that helped d...

Widely used hepatitis B drug spurs HIV drug resistance

A Johns Hopkins study has proven false established medical practice that an antiretroviral drug widely used to treat hepatitis B liver infections was safe to use on its own in patients co-infected with HIV. Their findings demonstrate that treatment with entecavir leads to cross-resistance to other...

Statins stop hepatitis C virus from replicating

A new study shows that statins, which are typically used as anti-cholesterol medications, can inhibit the replication of the hepatitis C virus (HCV). They could replace ribavirin in combination therapy with interferon. These findings are published in the July 2006 issue of Hepatology, the official ...

Study details hepatitis C ability to block immune system response

The study was published in an advance online edition of the Proceedings of the National Academy of Sciences on May 17. Hepatitis C virus (HCV) is a worldwide public health problem. The World Health Organization estimates that 170 million people worldwide are chronically infected and that between...

Cyclosporine inhibits hepatitis C virus in vitro

Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro. The result...

U of S researchers develop new vaccine candidate against hepatitis C

Researchers at the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine candidate for hepatitis C, leading to hope in the fight against a disease for which no vaccines are yet available. VIDO is the first in Canada to show that this vaccination ...

Texas scientists discover how a hepatitis C protein promotes liver cancer

Scientists at the University of Texas Medical Branch at Galveston (UTMB) have identified a key biochemical connection between the hepatitis C virus and liver cancer. The molecular mechanism is similar to the one that links the human papilloma virus (HPV), the cause of genital warts, and cervical ...

Past illegal blood donation in China linked to hepatitis C virus infection

Research in a rural province of central China has documented that illegal blood donation practices led to high hepatitis C virus (HCV) infection rates in blood and plasma donors during the 1980s and early 1990s, and that failure to screen for HCV in transfusion recipients increased their risk of in...

Studies clarify risk factors for mother-to-child transmission of hepatitis C virus

Breastfeeding does not raise the risk of mother-to-child transmission of hepatitis C virus (HCV), according to two new studies published in the December 1 issue of The Journal of Infectious Diseases, now available online. One study found that infant girls are twice as likely to be infected as in...

New tools used to control foodborne hepatitis A outbreaks related to green onions

Novel use of genetic testing methods helped public health officials control and limit the further spread of four outbreaks of foodborne hepatitis A virus in 2003 related to the consumption of green onions, according to a detailed analysis published in the October 15 issue of The Journal of Infectio...

Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied

NOAA/Virginia Sea Grant has awarded Virginia Tech $119,000 to study whether high hydrostatic pressure will inactivate Hepatitis A virus in both shucked and unshucked oysters. The project, led by Daniel Holliman, an M.D. with the High Pressure Processing Laboratory, and Laura Douglas, lab manager,...

Researchers create infectious hepatitis C virus in a test tube

A team of researchers led by scientists at The Rockefeller University has produced for the first time an infectious form of the hepatitis C virus (HCV) in laboratory cultures of human cells. The finding, reported in the June 9 issue of Science Express, will allow scientists to study every stage of ...

Identification of specific genes predicts which patients will respond to Hepatitis C treatment

For the first time, physicians at University Health Network and University of Toronto have identified a small subset of genes that can predict whether a patient with chronic Hepatitis C will be able to respond to current treatments. These genes could also become the basis of a simple new test in...

Scalpel-free surgery could reduce risk of HIV and hepatitis exposure for health care workers

While the incidence of disease from HIV and hepatitis is increasing in the United States, little is known about their prevalence in patients undergoing surgery. Now, researchers have shown that nearly 40 percent of surgeries at The Johns Hopkins Hospital occur in patients who tested positive for a ...

FDA Approves New Treatment for Chronic Hepatitis B

The Food and Drug Administration (FDA) announced the approval of Baraclude (entecavir) tablets and oral solution for the treatment of chronic hepatitis B in adults. Chronic hepatitis B is a serious disease caused by the hepatitis B virus (HBV) that attacks the liver. The virus can cause lifelong in...

Natural Killers Could Lead to New Hepatitis Treatments

Researchers have discovered that natural killer T (NKT) cells, the immune system's sentinels, patrol the labyrinthine blood vessels of the liver for invaders or signs of tissue damage and demonstrate a dogged behavior not seen before in other T cells. The new studies show that NKT cells crawl alo...

UCLA study assesses cost-effectiveness of Hepatitis B drugs

Researchers at UCLA and the Veterans Affairs Greater Los Angeles Healthcare System conducted the largest and most comprehensive study in comparing the cost-effectiveness of current modern drugs for treating hepatitis B -- a disease affecting 350 million worldwide. Published in the May 17 Annals ...

Norovirus, AIDS vaccine and Hepatitis Virus

Norovirus Prevalent in Those Suffering from Traveler's Diarrhea Norovirus may be the most common cause of travelers' diarrhea for United States citizens returning from Mexico and Guatamala say researchers from the U.S., Guatemala, Mexico and Sweden. Their findings appear in the March 2005 issue ...

Scientists Replicate Hepatitis C Virus in Laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the l...

Stem cell research: From molecular physiology to therapeutic applications

...undation's "Grand Challenges in Global Health". He obtained $1.9 million for his proposal to use stem cells to create mouse models for testing HIV and hepatitis C vaccines. Professor Deng has written a summary of recent progress in human embryonic and inducible pluripotent stem cell differentiation into functi...
Other Tags
(Date:7/30/2014)... epigenetic processes to regulate its genes, and adapt to ... of the genome regulation taking place in the truffle, ... Biology and illustrates how the truffle deals with ... authors say this may shed light on how traits ... (Tuber melanosporum), also known as Prigord truffles, have a ...
(Date:7/30/2014)... effects of climate change on the world,s animal ... factors, according to a new paper by a ... of Queensland, and other organizations. The authors claim ... the point when it comes to climate change. ... scientists focus on the "direct" threats of changing ...
(Date:7/30/2014)... The San Antonio Life Sciences Institute (SALSI), a joint ... (UTSA) and The University of Texas Health Science Center ... Postdoc Initiative Pilot Program. The winners, Emily Boice from ... will receive $25,000 for their project titled, "Novel engineered ... post-ischemic environment." , Boice and Huang,s research is focused ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
(Date:7/31/2014)... 31, 2014 The vineyards are lush, and ... harvest. And, to celebrate, folks are gearing up for the ... 6 and 7, 2014 along the Leelanau Peninsula Wine ... walk or run through the vineyards start-ing at 9:00 a.m. ... A unique course between rows of grapevines offers an experience ...
(Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... Guinness International Champions Cup Finals tickets at the Sun ... 2014 Guinness International Champions Cup is now underway. Residents and ... to be able to watch the Guinness International Champions Cup ... The eight teams competing in the tournament have been split ...
(Date:7/31/2014)... Denver, Colorado (PRWEB) July 31, 2014 ... commonly doctors recommend pain killers for this health problem. ... reveals that this new program was created by Peter ... purpose to help sufferers from all over the world ... , If people wish to view pros and ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Andrie, Inc. V. ... , The Michigan Supreme Court has made the determination that ... use tax when the taxpayer was unable to prove during ... purchases. The Court reversed the Court of Appeals decision on ... the use tax exemption for purchases from Michigan sellers. The ...
Breaking Medicine News(10 mins):Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3
Other Contents